AstraZeneca PLC
AZNDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 8, 2025 | $0.52 | 2025-08-08 | 2025-08-08 |
| March 24, 2025 | $1.05 | 2025-02-21 | 2025-02-21 |
| September 9, 2024 | $0.50 | 2024-08-09 | 2024-08-09 |
| March 25, 2024 | $0.98 | 2024-02-22 | 2024-02-23 |
| September 11, 2023 | $0.47 | 2023-08-10 | 2023-08-11 |
Dividends Summary
- AstraZeneca PLC has issued 45 dividend payments over the past 22 years
- The most recent dividend was paid 103 days ago, on September 8, 2025
- The highest dividend payed out to investors during this period was $1.95 per share
- The average dividend paid during this period was $0.88 per share.
Company News
GSK received FDA approval to use gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients 12 years and older, based on successful clinical trial results showing non-inferiority to standard treatment.
The global gestational diabetes market is projected to grow from USD 9.44 billion in 2024 to USD 22.58 billion by 2034, driven by increasing awareness, technological innovations, and rising diabetes incidence during pregnancy.
AstraZeneca announced a $2 billion investment in expanding drug-making capabilities in Maryland, with two facilities in Frederick and Gaithersburg set to be fully operational by 2029, utilizing AI and automation in their processes.
President Trump announced a 100% tariff on branded and patented pharmaceutical products starting October 1, 2025, causing significant market disruption and raising concerns about global pharmaceutical supply chains and trade policy.
AstraZeneca reported strong Q2 results, beating estimates for earnings and sales. The company's key drugs like Tagrisso, Ultomiris, Farxiga, and Calquence performed well, while Lynparza and Imfinzi sales were slightly weak. AstraZeneca raised its sales and earnings growth expectations for the year, citing a strong first-half performance.
